BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hanger Inc. (Formerly known as Hanger Orthopedic Group, Inc.) (HGR) Reports Earnings of $0.50 Per Diluted Share for the Second Quarter 2012


8/2/2012 12:57:33 PM

AUSTIN, Texas, Aug. 1, 2012 /PRNewswire/ -- Hanger, Inc. (NYSE: HGR) announced net sales of $251.8 million for the quarter ended June 30, 2012, an increase of $17.0 million, or 7.2%, from $234.8 million for the second quarter of 2011. Diluted earnings per share increased 11.1% to $0.50 for the second quarter of 2012 compared to diluted earnings per share of $0.45 in the same period in 2011.

The increase in net sales of $17.0 million, or 7.2%, for the second quarter of 2012 was the result of an $8.8 million, or 4.6%, increase in same-center sales in the patient-care services segment; a $5.9 million increase from acquired entities; a $1.8 million, or 7.2%, increase in sales in the distribution segment; and a $0.3 million increase from the therapeutic solutions segment. The increase in revenues, together with continued expense control, resulted in an 8.6%, or $2.8 million, increase in income from operations to $35.7 million for the three months ended June 30, 2012 compared to income from operations of $32.9 million for the same period in 2011.

Net sales for the six months ended June 30, 2012 increased $34.6 million, or 8.0%, to $469.8 million from $435.2 million in 2011. The sales increase was driven by a $20.1 million, or 5.7%, increase in same-center sales in the patient-care services segment; a $10.5 million increase from acquired entities; a $4.6 million, or 9.4%, increase in sales in the distribution segment; and a $0.6 million decrease from the therapeutic solutions segment. The increase in sales resulted in a 14.3%, or $0.09 per diluted share, increase in diluted earnings per share to $0.72 for the six months ended June 30, 2012 from $0.63 in the same period in 2011.

The Company's cash flow from operations increased $16.4 million to $27.0 million during the six months ended June 30, 2012 compared to $10.6 million in 2011. Through July 2012, the Company acquired seven patient care companies comprised of thirteen clinics with annualized revenue of $12.8 million. As of June 30, 2012, the Company had $141.1 million in total liquidity, which included $41.6 million of cash and $99.5 million available under its revolving credit facility, net of $0.5 million in letters of credit. The Company's leverage ratio, as defined in its credit facilities, improved to 2.9 at June 30, 2012 from 3.0 at December 31, 2011.

"We continue to deliver strong revenue growth in our patient-care services and our distribution segments. This, combined with solid operational execution demonstrated by our talented employees around the country, has resulted in 11.1% growth in diluted earnings per share," commented Vinit K. Asar, Chief Executive Officer of Hanger. "Our operations continue to generate good cash flow as we execute our planned investments in programs, acquisitions, and infrastructure improvements that will continue to provide a sustainable platform for future growth."

The Company expects full year 2012 revenues between $970 million and $990 million resulting from a comparable store sales growth in our patient-care services segment of 3% to 5% and growth in our distribution segment of 3% to 5%. We expect flat to slightly higher revenues in our therapeutic services segment for the year, with sales in the first half of the year down then trending up the second half as the rate of new contract sales accelerates. The Company has raised the lower end of its earnings guidance range and now anticipates diluted earnings per share between $1.75 and $1.79, excluding approximately $0.01 per diluted share in one-time training costs related to the implementation of Janus, the Company's new practice management and billing system. As in past years, the Company's goal is to increase operating margins by twenty to forty basis points. The Company anticipates generating cash flow from operations between $70 million and $80 million in 2012 and investing a total of $40 million to $50 million in capital additions. The Company will continue its acquisition program with a goal of closing acquisitions that total approximately $20 million in annualized revenues.

A conference call to discuss these results is scheduled to begin at 9:00 a.m., EDT, on Thursday, August 2, 2012. Those wishing to participate should call 1-877-312-5846. In addition, a replay will be available until Friday, August 10, 2012, by dialing 1-855-859-2056 and referencing Conference ID # 88640671.

About Hanger - Hanger, Inc., headquartered in Austin, Texas, is the world's premier provider for services and products that enhance human physical capability. Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger is steeped in 150 years of clinical excellence and innovation. Hanger provides orthotic and prosthetic patient care services, distributes O&P devices and components, and provides therapeutic solutions to the broader post-acute market. Hanger is the largest owner and operator of orthotic and prosthetic patient care clinics with in excess of 700 O&P patient care clinics located in 45 states and the District of Columbia. Hanger, through its subsidiary Southern Prosthetic Supply, Inc, is also the largest distributor of branded and private label O&P devices and components in the United States. Hanger provides therapeutic solutions through its subsidiaries Innovative Neurotronics and Accelerated Care Plus. Innovative Neurotronics introduces emerging neuromuscular technologies developed through independent research in a collaborative effort with industry suppliers worldwide. Accelerated Care Plus is a developer of specialized rehabilitation technologies and the nation's leading provider of evidence-based clinical programs for post-acute rehabilitation serving more than 4,000 long-term care facilities and other sub-acute rehabilitation providers throughout the U.S. For more information on Hanger, visit www.hanger.com and follow us at www.Facebook.com/HangerNews, www.Twitter.com/HangerNews, and www.YouTube.com/HangerNews.

This document contains forward-looking statements relating to the Company's results of operations. The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. Statements relating to future results of operations in this document reflect the current views of management. However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products and the other factors identified in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934. The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES